83_FR_27732 83 FR 27618 - Patient-Focused Drug Development: Collecting Comprehensive and Representative Input; Draft Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders; Availability

83 FR 27618 - Patient-Focused Drug Development: Collecting Comprehensive and Representative Input; Draft Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders; Availability

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Federal Register Volume 83, Issue 114 (June 13, 2018)

Page Range27618-27619
FR Document2018-12636

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry, FDA staff, and other stakeholders entitled ``Patient-Focused Drug Development: Collecting Comprehensive and Representative Input.'' This guidance (Guidance 1) is the first of a series of four methodological guidance documents that FDA committed to develop to address in a stepwise manner how to collect and submit information from patients and caregivers for medical product development and regulatory decision making.

Federal Register, Volume 83 Issue 114 (Wednesday, June 13, 2018)
[Federal Register Volume 83, Number 114 (Wednesday, June 13, 2018)]
[Notices]
[Pages 27618-27619]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-12636]



[[Page 27618]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2018-D-1893]


Patient-Focused Drug Development: Collecting Comprehensive and 
Representative Input; Draft Guidance for Industry, Food and Drug 
Administration Staff, and Other Stakeholders; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing 
the availability of a draft guidance for industry, FDA staff, and other 
stakeholders entitled ``Patient-Focused Drug Development: Collecting 
Comprehensive and Representative Input.'' This guidance (Guidance 1) is 
the first of a series of four methodological guidance documents that 
FDA committed to develop to address in a stepwise manner how to collect 
and submit information from patients and caregivers for medical product 
development and regulatory decision making.

DATES: Submit either electronic or written comments on the draft 
guidance by September 11, 2018 to ensure that the Agency considers your 
comment on this draft guidance before it begins work on the final 
version of the guidance.

ADDRESSES: You may submit comments on any guidance at any time as 
follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments. Comments submitted 
electronically, including attachments, to https://www.regulations.gov 
will be posted to the docket unchanged. Because your comment will be 
made public, you are solely responsible for ensuring that your comment 
does not include any confidential information that you or a third party 
may not wish to be posted, such as medical information, your or anyone 
else's Social Security number, or confidential business information, 
such as a manufacturing process. Please note that if you include your 
name, contact information, or other information that identifies you in 
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential 
information that you do not wish to be made available to the public, 
submit the comment as a written/paper submission and in the manner 
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper 
submissions): Dockets Management Staff (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets 
Management Staff, FDA will post your comment, as well as any 
attachments, except for information submitted, marked and identified, 
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No. 
FDA-2018-D-1893 for ``Patient-Focused Drug Development: Collecting 
Comprehensive and Representative Input; Draft Guidance for Industry, 
Food and Drug Administration Staff, and Other Stakeholders; 
Availability.'' Received comments will be placed in the docket and, 
except for those submitted as ``Confidential Submissions,'' publicly 
viewable at https://www.regulations.gov or at the Dockets Management 
Staff between 9 a.m. and 4 p.m., Monday through Friday.
     Confidential Submissions--To submit a comment with 
confidential information that you do not wish to be made publicly 
available, submit your comments only as a written/paper submission. You 
should submit two copies total. One copy will include the information 
you claim to be confidential with a heading or cover note that states 
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will 
review this copy, including the claimed confidential information, in 
its consideration of comments. The second copy, which will have the 
claimed confidential information redacted/blacked out, will be 
available for public viewing and posted on https://www.regulations.gov. 
Submit both copies to the Dockets Management Staff. If you do not wish 
your name and contact information to be made publicly available, you 
can provide this information on the cover sheet and not in the body of 
your comments and you must identify this information as 
``confidential.'' Any information marked as ``confidential'' will not 
be disclosed except in accordance with 21 CFR 10.20 and other 
applicable disclosure law. For more information about FDA's posting of 
comments to public dockets, see 80 FR 56469, September 18, 2015, or 
access the information at: https://www.thefederalregister.org/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or 
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in 
the heading of this document, into the ``Search'' box and follow the 
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, 
Rm. 1061, Rockville, MD 20852.
    You may submit comments on any guidance at any time (see 21 CFR 
10.115(g)(5)).
    Submit written requests for single copies of the draft guidance to 
the Division of Drug Information, Center for Drug Evaluation and 
Research, Food and Drug Administration, 10001 New Hampshire Ave., 
Hillandale Building, 4th Floor, Silver Spring, MD 20993-0002. Send one 
self-addressed adhesive label to assist that office in processing your 
requests. See the SUPPLEMENTARY INFORMATION section for electronic 
access to the draft guidance document.

FOR FURTHER INFORMATION CONTACT: Meghana Chalasani, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 51, Rm. 1146, Silver Spring, MD 20993-0002, 240-
402-6525, Fax: 301-847-8443, [email protected].

SUPPLEMENTARY INFORMATION: 

I. Background

    FDA is announcing availability of a draft guidance for industry, 
FDA staff, and other stakeholders entitled ``Patient-Focused Drug 
Development: Collecting Comprehensive and Representative Input.'' This 
guidance (Guidance 1) is the first of a series of four guidance 
documents that FDA committed to develop to address in a stepwise manner 
how stakeholders (patients, researchers, medical product developers, 
and others) can collect and submit information from patients and 
caregivers for medical product development and regulatory decision 
making. This series of guidance documents is intended to facilitate the 
advancement and use of systematic approaches to collect and use robust 
and meaningful patient and caregiver input that can more consistently 
inform medical product development and regulatory decision making. The 
purpose of Guidance 1 is to present methods for collecting information 
on the patient experience that is representative of the intended 
population to inform the development and evaluation of medical products

[[Page 27619]]

throughout the medical product lifecycle. In addition, this document 
discusses methods on how to operationalize and standardize the 
collection, analysis, and dissemination of patient experience data. 
Guidance 1 also includes a glossary of terms that will be used in one 
or more of the series of four guidance documents.
    This draft guidance is being issued consistent with FDA's good 
guidance practices regulation (21 CFR 10.115). The draft guidance, when 
finalized, will represent the current thinking of FDA on ``Patient-
Focused Drug Development: Collecting Comprehensive and Representative 
Input.'' It does not establish any rights for any person and is not 
binding on FDA or the public. You can use an alternative approach if it 
satisfies the requirements of the applicable statutes and regulations. 
This guidance is not subject to Executive Order 12866.

II. Additional Information

    Section 3002 of Title III, Subtitle A of the 21st Century Cures Act 
(Pub. L. 114-255) directs FDA to develop patient-focused drug 
development guidance to address a number of areas, including under 
section 3002(c)(1) (methodological approaches), which are relevant and 
objective and ensure that such data are accurate and representative of 
the intended population, that a person seeking to collect patient 
experience data to inform regulatory decision making may use.
    In addition, FDA committed to meet certain performance goals under 
the sixth authorization of the Prescription Drug User Fee Act. These 
goal commitments were developed in consultation with patient and 
consumer advocates, healthcare professionals, and other public 
stakeholders, as part of negotiations with regulated industry. Section 
I.J.1. of the commitment letter, ``Enhancing the Incorporation of the 
Patient's Voice in Drug Development and Decision-Making,'' (https://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM511438.pdf) outlines work, including the development of a series of 
guidance documents and associated public workshops to facilitate the 
advancement and use of systematic approaches to collect and utilize 
robust and meaningful patient and caregiver input that can more 
consistently inform drug development, and, as appropriate, regulatory 
decision making.

III. Electronic Access

    Persons with access to the internet may obtain the draft guidance 
at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm or https://www.regulations.gov.

    Dated: June 7, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018-12636 Filed 6-12-18; 8:45 am]
 BILLING CODE 4164-01-P



                                              27618                        Federal Register / Vol. 83, No. 114 / Wednesday, June 13, 2018 / Notices

                                              DEPARTMENT OF HEALTH AND                                public, submit the comment as a                        the information at: https://www.gpo.gov/
                                              HUMAN SERVICES                                          written/paper submission and in the                    fdsys/pkg/FR-2015-09-18/pdf/2015-
                                                                                                      manner detailed (see ‘‘Written/Paper                   23389.pdf.
                                              Food and Drug Administration                            Submissions’’ and ‘‘Instructions’’).                      Docket: For access to the docket to
                                              [Docket No. FDA–2018–D–1893]                                                                                   read background documents or the
                                                                                                      Written/Paper Submissions
                                                                                                                                                             electronic and written/paper comments
                                              Patient-Focused Drug Development:                          Submit written/paper submissions as                 received, go to https://
                                              Collecting Comprehensive and                            follows:                                               www.regulations.gov and insert the
                                              Representative Input; Draft Guidance                       • Mail/Hand delivery/Courier (for                   docket number, found in brackets in the
                                              for Industry, Food and Drug                             written/paper submissions): Dockets                    heading of this document, into the
                                              Administration Staff, and Other                         Management Staff (HFA–305), Food and                   ‘‘Search’’ box and follow the prompts
                                              Stakeholders; Availability                              Drug Administration, 5630 Fishers                      and/or go to the Dockets Management
                                                                                                      Lane, Rm. 1061, Rockville, MD 20852.                   Staff, 5630 Fishers Lane, Rm. 1061,
                                              AGENCY:    Food and Drug Administration,                   • For written/paper comments                        Rockville, MD 20852.
                                              HHS.                                                    submitted to the Dockets Management                       You may submit comments on any
                                              ACTION:   Notice of availability.                       Staff, FDA will post your comment, as                  guidance at any time (see 21 CFR
                                                                                                      well as any attachments, except for                    10.115(g)(5)).
                                              SUMMARY:    The Food and Drug                           information submitted, marked and
                                              Administration (FDA or Agency) is                                                                                 Submit written requests for single
                                                                                                      identified, as confidential, if submitted              copies of the draft guidance to the
                                              announcing the availability of a draft                  as detailed in ‘‘Instructions.’’
                                              guidance for industry, FDA staff, and                                                                          Division of Drug Information, Center for
                                                                                                         Instructions: All submissions received
                                              other stakeholders entitled ‘‘Patient-                                                                         Drug Evaluation and Research, Food
                                                                                                      must include the Docket No. FDA–
                                              Focused Drug Development: Collecting                                                                           and Drug Administration, 10001 New
                                                                                                      2018–D–1893 for ‘‘Patient-Focused Drug
                                              Comprehensive and Representative                                                                               Hampshire Ave., Hillandale Building,
                                                                                                      Development: Collecting
                                              Input.’’ This guidance (Guidance 1) is                  Comprehensive and Representative                       4th Floor, Silver Spring, MD 20993–
                                              the first of a series of four                           Input; Draft Guidance for Industry, Food               0002. Send one self-addressed adhesive
                                              methodological guidance documents                       and Drug Administration Staff, and                     label to assist that office in processing
                                              that FDA committed to develop to                        Other Stakeholders; Availability.’’                    your requests. See the SUPPLEMENTARY
                                                                                                                                                             INFORMATION section for electronic
                                              address in a stepwise manner how to                     Received comments will be placed in
                                              collect and submit information from                     the docket and, except for those                       access to the draft guidance document.
                                              patients and caregivers for medical                     submitted as ‘‘Confidential                            FOR FURTHER INFORMATION CONTACT:
                                              product development and regulatory                      Submissions,’’ publicly viewable at                    Meghana Chalasani, Center for Drug
                                              decision making.                                        https://www.regulations.gov or at the                  Evaluation and Research, Food and
                                              DATES: Submit either electronic or                      Dockets Management Staff between 9                     Drug Administration, 10903 New
                                              written comments on the draft guidance                  a.m. and 4 p.m., Monday through                        Hampshire Ave., Bldg. 51, Rm. 1146,
                                              by September 11, 2018 to ensure that                    Friday.                                                Silver Spring, MD 20993–0002, 240–
                                              the Agency considers your comment on                       • Confidential Submissions—To                       402–6525, Fax: 301–847–8443,
                                              this draft guidance before it begins work               submit a comment with confidential                     Meghana.Chalasani@fda.hhs.gov.
                                              on the final version of the guidance.                   information that you do not wish to be                 SUPPLEMENTARY INFORMATION:
                                              ADDRESSES: You may submit comments                      made publicly available, submit your
                                                                                                      comments only as a written/paper                       I. Background
                                              on any guidance at any time as follows:
                                                                                                      submission. You should submit two                        FDA is announcing availability of a
                                              Electronic Submissions                                  copies total. One copy will include the                draft guidance for industry, FDA staff,
                                                Submit electronic comments in the                     information you claim to be confidential               and other stakeholders entitled ‘‘Patient-
                                              following way:                                          with a heading or cover note that states               Focused Drug Development: Collecting
                                                • Federal eRulemaking Portal:                         ‘‘THIS DOCUMENT CONTAINS                               Comprehensive and Representative
                                              https://www.regulations.gov. Follow the                 CONFIDENTIAL INFORMATION.’’ The                        Input.’’ This guidance (Guidance 1) is
                                              instructions for submitting comments.                   Agency will review this copy, including                the first of a series of four guidance
                                              Comments submitted electronically,                      the claimed confidential information, in               documents that FDA committed to
                                              including attachments, to https://                      its consideration of comments. The                     develop to address in a stepwise manner
                                              www.regulations.gov will be posted to                   second copy, which will have the                       how stakeholders (patients, researchers,
                                              the docket unchanged. Because your                      claimed confidential information                       medical product developers, and others)
                                              comment will be made public, you are                    redacted/blacked out, will be available                can collect and submit information from
                                              solely responsible for ensuring that your               for public viewing and posted on                       patients and caregivers for medical
                                              comment does not include any                            https://www.regulations.gov. Submit                    product development and regulatory
                                              confidential information that you or a                  both copies to the Dockets Management                  decision making. This series of guidance
                                              third party may not wish to be posted,                  Staff. If you do not wish your name and                documents is intended to facilitate the
                                              such as medical information, your or                    contact information to be made publicly                advancement and use of systematic
                                              anyone else’s Social Security number, or                available, you can provide this                        approaches to collect and use robust
                                              confidential business information, such                 information on the cover sheet and not                 and meaningful patient and caregiver
                                              as a manufacturing process. Please note                 in the body of your comments and you                   input that can more consistently inform
                                              that if you include your name, contact                  must identify this information as                      medical product development and
amozie on DSK3GDR082PROD with NOTICES1




                                              information, or other information that                  ‘‘confidential.’’ Any information marked               regulatory decision making. The
                                              identifies you in the body of your                      as ‘‘confidential’’ will not be disclosed              purpose of Guidance 1 is to present
                                              comments, that information will be                      except in accordance with 21 CFR 10.20                 methods for collecting information on
                                              posted on https://www.regulations.gov.                  and other applicable disclosure law. For               the patient experience that is
                                                • If you want to submit a comment                     more information about FDA’s posting                   representative of the intended
                                              with confidential information that you                  of comments to public dockets, see 80                  population to inform the development
                                              do not wish to be made available to the                 FR 56469, September 18, 2015, or access                and evaluation of medical products


                                         VerDate Sep<11>2014   18:01 Jun 12, 2018   Jkt 244001   PO 00000   Frm 00081   Fmt 4703   Sfmt 4703   E:\FR\FM\13JNN1.SGM   13JNN1


                                                                           Federal Register / Vol. 83, No. 114 / Wednesday, June 13, 2018 / Notices                                                  27619

                                              throughout the medical product                          ComplianceRegulatoryInformation/                          The Subcommittee on Harmonization
                                              lifecycle. In addition, this document                   Guidances/default.htm or https://                      (SOH) was established by SACHRP at its
                                              discusses methods on how to                             www.regulations.gov.                                   July 2009 meeting and charged with
                                              operationalize and standardize the                        Dated: June 7, 2018.                                 identifying and prioritizing areas in
                                              collection, analysis, and dissemination                 Leslie Kux,
                                                                                                                                                             which regulations and/or guidelines for
                                              of patient experience data. Guidance 1                                                                         human subjects research adopted by
                                                                                                      Associate Commissioner for Policy.
                                              also includes a glossary of terms that                                                                         various agencies or offices within HHS
                                              will be used in one or more of the series               [FR Doc. 2018–12636 Filed 6–12–18; 8:45 am]
                                                                                                                                                             would benefit from harmonization,
                                              of four guidance documents.                             BILLING CODE 4164–01–P                                 consistency, clarity, simplification and/
                                                 This draft guidance is being issued                                                                         or coordination.
                                              consistent with FDA’s good guidance                                                                               The SACHRP meeting will open to the
                                              practices regulation (21 CFR 10.115).                   DEPARTMENT OF HEALTH AND
                                                                                                      HUMAN SERVICES                                         public at 8:30 a.m., on Tuesday, July 10,
                                              The draft guidance, when finalized, will                                                                       2018, followed by opening remarks from
                                              represent the current thinking of FDA                                                                          Dr. Jerry Menikoff, Director of OHRP
                                                                                                      Meeting of the Secretary’s Advisory
                                              on ‘‘Patient-Focused Drug Development:                                                                         and Dr. Stephen Rosenfeld, SACHRP
                                                                                                      Committee on Human Research
                                              Collecting Comprehensive and                                                                                   Chair.
                                              Representative Input.’’ It does not                     Protections
                                                                                                                                                                The SAS and SOH subcommittees
                                              establish any rights for any person and                 AGENCY:  Office of the Assistant                       will present their recommendations
                                              is not binding on FDA or the public.                    Secretary for Health, Office of the                    regarding the description of ‘‘key
                                              You can use an alternative approach if                  Secretary, Department of Health and                    information,’’ as required by the revised
                                              it satisfies the requirements of the                    Human Services.                                        Common Rule at § 46.116(a)(5)(i). This
                                              applicable statutes and regulations. This               ACTION: Notice.                                        will be followed by a discussion of the
                                              guidance is not subject to Executive
                                                                                                                 Pursuant to Section 10(a) of                application of the revised Common
                                              Order 12866.                                            SUMMARY:
                                                                                                      the Federal Advisory Committee Act,                    Rule’s exemptions at 46.104(d) to FDA-
                                              II. Additional Information                                                                                     regulated research, and
                                                                                                      U.S.C. Appendix 2, notice is hereby
                                                 Section 3002 of Title III, Subtitle A of             given that the Secretary’s Advisory                    recommendations on the interpretation
                                              the 21st Century Cures Act (Pub. L. 114–                Committee on Human Research                            of § 46.104(d)(1) and (2) for HHS funded
                                              255) directs FDA to develop patient-                    Protections (SACHRP) will hold a                       research.
                                              focused drug development guidance to                    meeting that will be open to the public.                  The Wednesday, July 11, meeting will
                                              address a number of areas, including                    Information about SACHRP and the full                  begin at 8:30 a.m. The SAS
                                              under section 3002(c)(1)                                meeting agenda will be posted on the                   subcommittee will present and discuss
                                              (methodological approaches), which are                  SACHRP website at: http://                             recommendations on the interpretation
                                              relevant and objective and ensure that                  www.dhhs.gov/ohrp/sachrp-committee/                    of ‘‘reasonably available’’ at § 46.408(b),
                                              such data are accurate and                              meetings/index.html.                                   as well as discuss issues surrounding
                                              representative of the intended                                                                                 payment to subjects for participation in
                                                                                                      DATES: The meeting will be held on
                                              population, that a person seeking to                                                                           research. Modifications to the previous
                                                                                                      Tuesday, July 10, 2018, from 8:30 a.m.
                                              collect patient experience data to inform                                                                      day’s work will be discussed and
                                                                                                      until 5:00 p.m., and Wednesday, July
                                              regulatory decision making may use.                                                                            finalized. The meeting will adjourn at
                                                                                                      11, 2018, from 8:30 a.m. until 4:00 p.m.
                                                 In addition, FDA committed to meet                                                                          approximately 4:00 p.m., July 11, 2018.
                                                                                                      ADDRESSES: 6001 Executive Boulevard,
                                              certain performance goals under the                                                                               Time for public comment sessions
                                              sixth authorization of the Prescription                 Conference Room A, Rockville,
                                                                                                                                                             will be allotted both days. On-site
                                              Drug User Fee Act. These goal                           Maryland 20852.
                                                                                                                                                             registration is required for participation
                                              commitments were developed in                           FOR FURTHER INFORMATION CONTACT: Julia
                                                                                                                                                             in the live public comment session.
                                              consultation with patient and consumer                  Gorey, J.D., Executive Director,                       Note that public comment must be
                                              advocates, healthcare professionals, and                SACHRP; U.S. Department of Health                      relevant to topics currently being
                                              other public stakeholders, as part of                   and Human Services, 1101 Wootton                       addressed by the SACHRP. Individuals
                                              negotiations with regulated industry.                   Parkway, Suite 200, Rockville,                         submitting written statements as public
                                              Section I.J.1. of the commitment letter,                Maryland 20852; telephone: 240–453–                    comment should provide their
                                              ‘‘Enhancing the Incorporation of the                    8141; fax: 240–453–6909; email address:                comments by email to SACHRP@
                                              Patient’s Voice in Drug Development                     SACHRP@hhs.gov.                                        hhs.gov or by fax to (240) 453–6909 at
                                              and Decision-Making,’’ (https://                        SUPPLEMENTARY INFORMATION: Under the                   least five business days prior to the
                                              www.fda.gov/downloads/ForIndustry/                      authority of 42 U.S.C. 217a, Section 222               meeting.
                                              UserFees/PrescriptionDrugUserFee/                       of the Public Health Service Act, as                      Public attendance at the meeting is
                                              UCM511438.pdf) outlines work,                           amended, SACHRP was established to                     limited to space available. Individuals
                                              including the development of a series of                provide expert advice and                              who plan to attend and need special
                                              guidance documents and associated                       recommendations to the Secretary of                    assistance, such as sign language
                                              public workshops to facilitate the                      Health and Human Services, through                     interpretation or other reasonable
                                              advancement and use of systematic                       the Assistant Secretary for Health, on                 accommodations, should notify the
                                              approaches to collect and utilize robust                issues and topics pertaining to or                     designated SACHRP point of contact at
                                              and meaningful patient and caregiver                    associated with the protection of human                the address/phone number listed above
                                              input that can more consistently inform                 research subjects.
amozie on DSK3GDR082PROD with NOTICES1




                                                                                                                                                             at least one week prior to the meeting.
                                              drug development, and, as appropriate,                     The Subpart A Subcommittee (SAS)
                                                                                                      was established by SACHRP in October                     Dated: June 7, 2018.
                                              regulatory decision making.
                                                                                                      2006 and is charged with developing                    Julia G. Gorey,
                                              III. Electronic Access                                  recommendations for consideration by                   Executive Director, Secretary’s Advisory
                                                 Persons with access to the internet                  SACHRP regarding the application of                    Committee on Human Research Protections.
                                              may obtain the draft guidance at http://                subpart A of 45 CFR part 46 in the                     [FR Doc. 2018–12662 Filed 6–12–18; 8:45 am]
                                              www.fda.gov/Drugs/Guidance                              current research environment.                          BILLING CODE 4150–36–P




                                         VerDate Sep<11>2014   18:01 Jun 12, 2018   Jkt 244001   PO 00000   Frm 00082   Fmt 4703   Sfmt 4703   E:\FR\FM\13JNN1.SGM   13JNN1



Document Created: 2018-06-12 23:59:17
Document Modified: 2018-06-12 23:59:17
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice of availability.
DatesSubmit either electronic or written comments on the draft guidance by September 11, 2018 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.
ContactMeghana Chalasani, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 1146, Silver Spring, MD 20993-0002, 240- 402-6525, Fax: 301-847-8443, [email protected]
FR Citation83 FR 27618 

2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR